<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36910458</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2754-0413</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>BMJ medicine</Title><ISOAbbreviation>BMJ Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of <b>patients</b> with long covid: target trial emulation based on ComPaRe e-cohort.</ArticleTitle><Pagination><StartPage>e000229</StartPage><MedlinePgn>e000229</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e000229</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjmed-2022-000229</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Target trial emulation based on ComPaRe e-cohort.</AbstractText><AbstractText Label="DATA SOURCE" NlmCategory="UNASSIGNED">ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of patients with long covid, in France.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Adult patients (aged &#x2265;18 years) enrolled in the ComPaRe cohort before 1 May 2021 were included in the study if they reported a confirmed or suspected SARS-CoV-2 infection, symptoms persistent for &gt;3&#x2009;weeks after onset, and at least one symptom attributable to long covid at baseline. Patients who received a first covid-19 vaccine injection were matched with an unvaccinated control group in a 1:1 ratio according to their propensity scores. Number of long covid symptoms, rate of complete remission of long covid, and proportion of patients reporting an unacceptable symptom state at 120 days were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">910 patients were included in the analyses (455 in the vaccinated group and 455 in the control group). By 120 days, vaccination had reduced the number of long covid symptoms (mean 13.0 (standard deviation 9.4) in the vaccinated group <i>v</i> 14.8 (9.8) in the control group; mean difference -1.8, 95%&#x2009;confidence interval -3.0 to -0.5) and doubled the rate of patients in remission (16.6% <i>v</i> 7.5%, hazard ratio 1.93, 95%&#x2009;confidence interval 1.18 to 3.14). Vaccination reduced the effect of long covid on patients' lives (mean score on the impact tool 24.3 (standard deviation 16.7) <i>v</i> 27.6 (16.7); mean difference -3.3, 95%&#x2009;confidence interval -5.7 to -1.0) and the proportion of patients with an unacceptable symptom state (38.9% <i>v</i> 46.4%, risk difference -7.4%, 95%&#x2009;confidence interval -14.5% to -0.3%). In the vaccinated group, two (0.4%) patients reported serious adverse events requiring admission to hospital.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In this study, covid-19 vaccination reduced the severity of symptoms and the effect of long covid on patients' social, professional, and family lives at 120 days in those with persistent symptoms of infection.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Viet-Thi</ForeName><Initials>VT</Initials><Identifier Source="ORCID">0000-0003-1863-6739</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9; and Universit&#xe9; Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, AP-HP, H&#xf4;pital H&#xf4;tel Dieu, F-75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrodeau</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, AP-HP, H&#xf4;pital H&#xf4;tel Dieu, F-75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldanha</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pane</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, AP-HP, H&#xf4;pital H&#xf4;tel Dieu, F-75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravaud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre d'Epid&#xe9;miologie Clinique, AP-HP, H&#xf4;pital H&#xf4;tel Dieu, F-75004 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Med</MedlineTA><NlmUniqueID>9918487584306676</NlmUniqueID><ISSNLinking>2754-0413</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ Med. 2023 Feb 1;2(1):e000470. doi: 10.1136/bmjmed-2022-000470</RefSource><PMID Version="1">36936263</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2023 Apr;165(7):19. doi: 10.1007/s15006-023-2552-5</RefSource><PMID Version="1">37016218</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword></KeywordList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>13</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36910458</ArticleId><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="doi">10.1136/bmjmed-2022-000229</ArticleId><ArticleId IdType="pii">bmjmed-2022-000229</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. London, UK; 2021. [Accessed 02 Sep 2021].</Citation></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, et al. . Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021;372:n693. 10.1136/bmj.n693</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine 2021;38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Porcher R, Pane I, et al. . Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun 2022;13:1812. 10.1038/s41467-022-29513-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine 2022;53:101624. 10.1016/j.eclinm.2022.101624</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. . Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022;399:2263&#x2013;4. 10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022;28:1461&#x2013;7. 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>LongCovidSOS . The impact of COVID vaccination on symptoms of long Covid. An international survey of 900 people with lived experience, 2021. Available: https://3ca26cd7-266e-4609-b25f-6f3d1497c4cf.filesusr.com/ugd/8bd4fe_a338597f76bf4279a851a7a4cb0e0a74.pdf [Accessed 03 Sep 2021].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D, Milne A, Samms E, et al. . Are vaccines safe in patients with long COVID? A prospective observational study. medRxiv 2021. 10.1101/2021.03.11.21253225</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, et al. . Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv 2022. 10.1101/2022.01.05.22268800</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.05.22268800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels K, et al. . Changes in the trajectory of long Covid symptoms following COVID-19 vaccination: community-based cohort study. medRxiv 2022. 10.1101/2021.12.09.21267516v1</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.09.21267516v1</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey D, Berrent D, Akrami A, et al. . Change in symptoms and immune response in people with post-acute sequelae of SARS-Cov-2 infection (PASC) after SARS-Cov-2 vaccination. medRxiv 2021. 10.1101/2021.07.21.21260391</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol 2022;23:194&#x2013;202. 10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 2016;183:758&#x2013;64. 10.1093/aje/kwv254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Ravaud P. Collaborative open platform E-cohorts for research acceleration in trials and epidemiology. J Clin Epidemiol 2020;124:139&#x2013;48. 10.1016/j.jclinepi.2020.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.04.021</ArticleId><ArticleId IdType="pubmed">32380177</ArticleId></ArticleIdList></Reference><Reference><Citation>Denscombe M. The Good Research Guide. Buckingham: Open University Press, 1997.</Citation></Reference><Reference><Citation>Tran V-T, Riveros C, Clepier B, et al. . Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients' lived experience. Clin Infect Dis 2022;74:278&#x2013;87. 10.1093/cid/ciab352</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Haute Autorit&#xe9; de Sant&#xe9; . Strat&#xe9;gie de vaccination contre le SARS-CoV-2 : Vaccination des personnes ayant un ant&#xe9;c&#xe9;dent de Covid-19; 2021.</Citation></Reference><Reference><Citation>Tubach F, Dougados M, Falissard B, et al. . Feeling good rather than feeling better matters more to patients. Arthritis Rheum 2006;55:526&#x2013;30. 10.1002/art.22110</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22110</ArticleId><ArticleId IdType="pubmed">16874795</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration . What is a serious adverse event?
2022. Available: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event [Accessed 04 Nov 2022].</Citation></Reference><Reference><Citation>Garc&#xed;a-Alb&#xe9;niz X, Hsu J, Bretthauer M, et al. . Effectiveness of screening colonoscopy to prevent colorectal cancer among Medicare beneficiaries aged 70 to 79 years. Ann Intern Med 2017;166:18&#x2013;26. 10.7326/M16-0758</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-0758</ArticleId><ArticleId IdType="pmc">PMC5417337</ArticleId><ArticleId IdType="pubmed">27669524</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . International classification of primary care, second edition (ICPC-2), 2003. Available: https://www.who.int/classifications/icd/adaptations/icpc2/en/ [Accessed 04 Apr 2020].</Citation></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083&#x2013;107. 10.1002/sim.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008;27:2037&#x2013;49. 10.1002/sim.3150</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3150</ArticleId><ArticleId IdType="pubmed">18038446</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotnitzky A, Robins J. Analysis of semi-parametric regression models with non-ignorable non-response. Stat Med 1997;16:81&#x2013;102. 10.1002/(SICI)1097-0258(19970115)16:1&amp;lt;81::AID-SIM473&amp;gt;3.0.CO;2-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19970115)16:1&amp;lt;81::AID-SIM473&amp;gt;3.0.CO;2-0</ArticleId><ArticleId IdType="pubmed">9004385</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med 2017;167:268&#x2013;74. 10.7326/M16-2607</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-2607</ArticleId><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 2019;188:l5657. 10.1136/bmj.l5657</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l5657</ArticleId><ArticleId IdType="pubmed">31645336</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T, Hirose M, Inoue Y, et al. . Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long COVID. J Med Virol 2022;94:3416&#x2013;20. 10.1002/jmv.27689</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27689</ArticleId><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. . Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis 2022. doi:10.1093/cid/ciac722. [Epub ahead of print: 02 Sep 2022].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A, et al. . Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur Respir J 2022:2200970. 10.1183/13993003.00970-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00970-2022</ArticleId><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>